<DOC>
	<DOCNO>NCT02384889</DOCNO>
	<brief_summary>This study multicenter , double-blind , placebo-controlled , 2:1 randomly assign , phase 1 clinical trial individual type 1 diabetes . It blind dose-ranging study enrol patient new onset type 1 diabetes document continued residual C-peptide production . After 4 week screen run-in period eligibility determine glycemic control optimize , subject 3-month double-masked treatment period either DFMO placebo . After 3 month wash-out period durability effect assess . Subjects randomly assign ( 6 DFMO ; 3 placebo cohort ) 1 4 sequential dose cohort .</brief_summary>
	<brief_title>DFMO Children With Type 1 Diabetes</brief_title>
	<detailed_description>This study repurposing alpha difluoromethylornithine ( DFMO ) order characterize effect persons new onset type 1 diabetes . In preliminary study mice , inhibition polyamine synthesis DFMO preserve β-cell insulin production delay diabetes onset . Polyamine modulation potential improve β cell health person T1D . The investigator propose decrease polyamine synthesis person new onset T1D improve marker ß cell health function . This double-masked , placebo-controlled dose-finding randomize multiple ascend dose study include 1-month screening period ; 3-month double-masked treatment period ; 3-month follow-up period . Subjects randomly assign 1 4 sequential dose cohort : DFMO nominal ( start ) dose 125 mg/m2 per day , 250 mg/m2 per day , 500 mg/m2 per day , 750 mg/m2 per day . Dose escalation do base upon whether dose limit toxicity observe whether suggestion effect biomarkers β-cell stress observe . At maximum dose , cohort expand order estimate biomarker activity . If suggestion effect dose-limiting toxicity 750 mg/m2 per day , 750 mg per day group enrol . Regardless dose expand , investigator evaluate efficacy treatment primary secondary outcome . The primary outcome endpoint study safety dos . In particular , dose-limiting toxicity know potential side effect DFMO ( thrombocytopenia , neutropenia , anemia , audiometric impairment ) review monitor internal safety review committee cohort enrol . Secondary outcome include biomarkers beta cell stress , measure insulin production/glycemia . Exploratory outcome include flow cytometry assessment B- T-cell subset , quantification polyamine intake excretion , pharmacokinetic DFMO concentration . Completion study facilitate future work study DFMO inhibitor pathways influence intracellular polyamine level , include non-steroidal inflammatory agent , novel polyamine transport inhibitor . .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>1 . Males females 1240 year age clinical diagnosis T1D within 2 8 month diagnosis time visit 2 . 2 . Random nonfasting Cpeptide level &gt; 0.2 pmol/mL visit 1 . 3 . Positive one follow diabetesrelated autoantibody ( mIAA , GADA , IA2A , ZnT8A ) 4 . Treatment naïve immunomodulatory agent 5 . Normal hear screening , define acceptable result puretone audiometry ( &lt; 20 decibel [ dB ] baseline threshold frequency 250 , 500 , 1000 , 2000 Hz 1 . Presence severe , active disease interfere dietary intake require use chronic medication , exception wellcontrolled hypothyroidism mild asthma require oral steroid . Presence psychiatric disorder affect ability participate study . 2 . Diabetes T1D 3 . Chronic illness know affect glucose metabolism ( e.g . Cushing syndrome , polycystic ovarian disorder , cystic fibrosis ) take medication affect glucose metabolism ( e.g . steroid , metformin ) 4 . Inability swallow pill 5 . Psychiatric impairment current use antipsychotic medication 6 . Any condition , investigator 's opinion , may compromise study participation may confound interpretation study result . 7 . Hematologic abnormality screen ( anemia , leukopenia ( particularly neutropenia ) , thrombocytopenia ) 8 . Impaired renal function ( assessed history BUN/Creatinine , DFMO renally excrete ) 9 . Female participant childbearing age must pregnant agree use effective form birth control abstinent study period . 10 . BMI &gt; 95 % age sex</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>